Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: James216440@xxxxxxxxx
- Date: Thu, 26 Jul 2007 17:34:10 -0700
On 25 Jul, 12:51, Jim Chinnis <jchin...@xxxxxxxxxxxxxxxx> wrote:
MarilynMann <ma...@xxxxxxxxxxx> wrote in part:
New analysis uncovers relationship between low LDL-cholesterol levels
and cancer
Note that this is a "new analysis" based on a less than rigorous pooling of
studies. Note that it also conflicts with the biggest randomized clinical
trial data. Note also that the effect size is very, very small.
--
Jim Chinnis Warrenton, Virginia, USA
The real problem with such a study as this is the exposure time. Even
if statin treatment resulted in statistically significant excess
cancers the treatment times of only a few years are simply way too
short to show that statins are the cause of the cancer. We already
know that statins are not rampant carcinogens from all the animal and
human testing. They are simply sort of garden variety slow acting
carcinogens like lots of things.
So any excess cancers seen in these studies are simply some side
effect of, for instance, a very mild immune defect that releases the
already existing cancer into an agressive state a bit faster then
would otherwise be expected. These studies were all only a few years
as I recall. What you would expect to see is a mild increase in
cancer rates in the early period of treatment. Then after a few years
the cancer rate should drop back to background rates or even lower,
particularly if you do not correct the data for the early onset
cancers. Then out at some 20 or 30 years of treatment you could
expect to start to see cancers resulting from statin treatment.
A very big hint in the pretty weak data package is cancers seen were
not specific. Virtually all chemical carcinogens strongly target
particular organs rather then cause a non specific distribution of
cancers.
In plain English these people were going to get cancer regardless of
treatment.
.
- Follow-Ups:
- Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: bigvince
- Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: Jim Chinnis
- Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- References:
- Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: MarilynMann
- Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: MarilynMann
- Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- From: Jim Chinnis
- Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- Prev by Date: Endogenous sex hormones levels in postmenopausal women undergoing carotid artery endarterectomy
- Next by Date: Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- Previous by thread: Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- Next by thread: Re: Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials
- Index(es):
Relevant Pages
|